Treatment for HER2-positive breast cancer depends on tumor size and spread but may involve a combination of chemotherapy, targeted therapy, monoclonal antibody therapy, and kinase inhibitors.

As I shift from an oncologist to a gynecologist for breast screenings, I examine both my reluctance to let go of the past and my hopes for the future. Low-dose oral minoxidil, the hair growth drug ...

When the HER2 gene is abnormal, it causes the cells to divide and grow at an uncontrolled ... Her cocktail consisted of Texotere, Carboplatin, Perjeta, and Herceptin. Of course, her younger brother, ...

在新版医保目录中，T-DXd可报销的适应症包括：既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌患者；既往在转移性疾病阶段接受过至少一种系统治疗的，或在辅助化疗期间或完成辅助化疗之后6个月内复发的，不可切除或转移性 ...

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label ...

The pathologic complete response rate was 66.3% in the nab-paclitaxel arm and 57.6% in the docetaxel-carboplatin arm. The combination of nab-paclitaxel, trastuzumab, and pertuzumab may provide ...

We established that under bladder instillation conditions, the toxin eliminated human, canine and mouse bladder cancer cells, including Her2-positive cells, with a LC50<1nM (<<intoxication dose ~1μM) ...